AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 81 min read$INBX

FORSYTH DOUGLAS purchased $287K of INBX (indirect holdings)

FORSYTH DOUGLAS purchased 2,500 indirectly-held shares of Inhibrx Biosciences, Inc. (INBX) at $114.65 ($0.29M total) on 2026-09-08.

Original reporting
SEC EDGAR · FORSYTH DOUGLAS
Published Sep 8, 2026, 8:26 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 8, 2026, 8:46 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$INBX
Bullish
medium confidence
Mentioned
$INBX
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$INBXBullishLow
01

Why it matters

The director's purchase modestly raises confidence but is unlikely to affect price materially.

02

Market read

Routine insider purchase with limited trading relevance.

03

What to watch

Potential upcoming clinical data could be the real driver, not the insider trade.

Relevance 5/10Novelty 4/10Timing: same-day filing

Background

SEC Form 4 filing discloses insider transactions for public companies.

Company-level read

Ticker impact

$INBXBullishMedium confidence
Context

Director Forsyth Douglas bought 2,500 INBX shares at $114.65 each, raising his holding to 227,064 shares.

Expected impact

Modest upside pressure in the short term.

Evidence & confidence

A director purchase, though modest in dollar size, can signal positive sentiment but is unlikely to move the stock significantly.

Market effects

Sector

Minimal impact on the biotech sector.

Regional

No regional effect.

Global

Negligible.

Counterpoint

What could challenge this read

The purchase may be routine portfolio rebalancing rather than a bullish signal.

Key entities

  • Company
    Inhibrx Biosciences, Inc.

    Biotech firm developing therapies.

  • Individual
    Forsyth Douglas

    Director of Inhibrx Biosciences.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

INBX insider trading history →

Related articles

SEP 8
$INBXMedAI 8/10

Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study

Inhibrx Biosciences (INBX) reported positive Phase 2 trial results for INBRX-106 combined with pembrolizumab in head and neck cancer. The combination showed a 48.3% response rate vs 26.5% for pembrolizumab alone, with 9.6-month median PFS. HPV+ patients saw even stronger results. The company plans to expand the trial and explore further applications. INBRX-106 is a hexavalent OX40 agonist.

prnewswire.com2 min
SEP 8
$INBXHighAI 8/10

Inhibrx stock jumps on positive cancer drug trial results

Inhibrx Biosciences (NASDAQ:INBX) shares rose 6% after reporting positive Phase 2 trial results for INBRX-106 combined with pembrolizumab in head and neck cancer. The combination showed a 48.3% response rate vs. 26.5% for pembrolizumab alone. The study included 63 patients, with notable improvements in HPV-positive patients. The company plans to expand the trial and align with the FDA for a potential accelerated pathway.

investing.com2 min
AUG 13
$INBXMedAI 8/10

Inhibrx Reports Second Quarter 2026 Financial Results

Inhibrx Biosciences (Nasdaq: INBX) reported Q2 2026 results. It received $100.0 million from Oxford Finance under a loan amendment that allows up to $325.0 million gross proceeds. Cash rose to $219.5 million as of Aug. 6. Q2 R&D was $23.9 million, net loss $36.7 million ($2.34/share). FDA accepted its ozekibart BLA with PDUFA April 14, 2027.

prnewswire.com4 min
AUG 13
$INBXMed

Inhibrx Biosciences, Inc. (INBX): Results of Operations and Financial Condition

Inhibrx Biosciences, Inc. (INBX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Inhibrx Reports Second Quarter 2026 Financial Results San Diego, CA, August 13, 2026 – Inhibrx Biosciences, Inc. (Nasdaq: INBX) (“Inhibrx” or the “Company”) today reported financial results for the second quarter of 2026. The biopharmaceutical company has two program

SEC EDGAR 8-K6 min
AUG 13
$INBXMedAI 8/10

FDA Sets April 2027 Goal Date for Inhibrx's Ozekibart

Inhibrx Biosciences (Nasdaq: INBX) reported Q2 2026 results and said the FDA accepted its BLA for ozekibart (INBRX-109) in conventional chondrosarcoma, assigning a PDUFA goal date of April 14, 2027. The company also amended its Oxford Finance loan for up to $325.0 million. Q2 net loss was $36.7 million; cash was $219.5 million as of Aug. 6, 2026.

stocktitan.net4 min